StockWatch
·
Pharmaceuticals
USFDA17 Nov 2026, 11:20 pm

Cipla Subsidiary InvaGen Inspection by USFDA Classified as NAI

AI Summary

Cipla Ltd announced that its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Hauppauge, New York, USA, underwent an inspection by the United States Food and Drug Administration (USFDA) from October 19-22, 2026. Following this inspection, the USFDA, via communication dated November 17, 2026, has classified the inspection as 'No Action Indicated' (NAI). This classification suggests that the inspection did not reveal any significant compliance issues that would warrant regulatory action.

Key Highlights

  • USFDA inspection conducted at Cipla's subsidiary, InvaGen Pharmaceuticals Inc.
  • Inspection took place at the Hauppauge, New York facility.
  • USFDA has classified the inspection outcome as 'No Action Indicated' (NAI).
  • NAI classification indicates no significant compliance issues were found.